Servier Email Format

Pharmaceutical Manufacturing
10,001-25,000 employees
Suresnes, France

Servier is an independent international pharmaceutical group specializing in cardiology, oncology, and neurology, with medicines distributed in more than 130 countries worldwide.

Find contacts at Servier

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@servier.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
1954
Headquarters
Suresnes, France
Revenue
$5B-$10B
FUNDING Stage
Private
Key Executives
Olivier Laureau (President and CEO of the Servier Group and the Servier International Foundation for Research), Pascal Lemaire (Executive Vice President Finance), Stephane Mascarau (Executive Vice President, World Operations)

Tech Stack

Salesforce

CRM

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Servier?

Servier uses the first.last format on servier.com, so Jane Smith would be jane.smith@servier.com.

What are Servier's main therapeutic areas?

Servier focuses on three core therapeutic areas: oncology, cardiometabolism and the treatment of venous diseases, and neurology. The oncology division emphasizes precision medicine for hard-to-treat cancers, including IDH-mutated cancers.

How many countries are Servier's medicines distributed in?

Servier distributes its medicines in over 130 countries and generates around 82% of its sales outside France, reflecting its broad global footprint across Europe, Asia, the Americas, and beyond.

What is Servier's TIBSOVO used to treat?

TIBSOVO (ivosidenib) is Servier's FDA-approved oncology drug targeting IDH1-mutated cancers. It has received approvals for acute myeloid leukemia, IDH1-mutated cholangiocarcinoma, and myelodysplastic syndromes, and is a cornerstone of Servier's precision oncology portfolio.

Can Clay help me find and verify a Servier contact's email address?

Yes, Clay can help you confirm that a Servier contact follows the first.last@servier.com pattern and verify the address before outreach, making it easier to build accurate prospect lists targeting Servier's 14,237-person global organization.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles